Enlivex Ltd.

Enlivex Ltd. is a clinical-stage immunotherapy company engaged in advancing therapies aimed at extending health span and quality of life. The company operates a dual model encompassing quality longevity therapeutics alongside a corporate treasury strategy focused on decentralized prediction markets infrastructure. Its principal product candidate is Allocetra, an off-the-shelf, universal cell therapy designed to restore macrophage homeostasis and rebalance the immune system to treat multiple inflammatory conditions, with a primary clinical indication in osteoarthritis. Potential recipients and target beneficiaries of the company's therapeutic candidates include patients suffering from debilitating and life-threatening conditions characterized by severe unmet medical needs.

The business operates as a non-accelerated filer organized under the laws of the State of Israel, conducting its research, development, and administrative activities through its corporate base. The company maintains its principal executive offices and headquarters at 14 Einstein Street in Ness Ziona, Israel. No commercial sales operations, retail store network, or active foreign branch facilities are reported in the provided text.

Summary of the business section of Enlivex's latest annual report, written by StockData.

“the Company had 34 full time employees, of whom 26 employees are involved in product development and eight employees provide general”